Research cutoff: September 21, 2026. This is a pre-results guide. Johnson & Johnson has scheduled its third-quarter 2026 investor call for October 13. The quarter’s results have not yet been released as of this research cutoff. Recheck the company’s investor-relations page before making a decision after that date.
The useful October question for JNJ stock is not a precise share-price target: it is whether the October 13 results support the full-year sales and adjusted-earnings outlook that management raised in July. Separate the two operating engines, Innovative Medicine and MedTech; then compare reported growth, operational growth and cash generation. An earnings beat on one measure alone may not settle the investment case.
What happens in October?
In its official August 31 announcement, Johnson & Johnson said it would release its Q3 press release at approximately 6:45 a.m. Eastern Time on Tuesday, October 13, followed by an investor conference call at 8:30 a.m. Eastern Time. These are company-announced times, not a guarantee that any individual trading platform will display figures instantly. The key follow-up is the filed release, the presentation and management’s answers, not only the first headline.
This article is intentionally published before the event. A later Q3 result, new guidance or changed schedule would require an update. Do not confuse this October framework with a report of actual third-quarter revenue or profit.
The July baseline investors can verify
Johnson & Johnson’s July 15 Q2 release reported $25.310 billion in quarterly sales, up 6.6% year over year on a reported basis. Diluted GAAP earnings per share were $2.27; adjusted EPS, a company-defined non-GAAP measure, was $2.90. The adjusted number excludes specified items and should not be silently substituted for GAAP profit.
In that same release, the company lifted its full-year 2026 estimated reported-sales range to $100.8 billion–$101.4 billion, with a $101.1 billion midpoint, and its adjusted EPS range to $11.60–$11.75, with an $11.68 midpoint. These were July management estimates, not October actuals. When Q3 arrives, compare any revised outlook with both the July range and the assumptions behind it. An unchanged midpoint after a strong quarter can mean different things depending on remaining-quarter expectations and currency.
Innovative Medicine: what changes the thesis?
Q2 Innovative Medicine sales were $16.384 billion, up 7.8% as reported and 6.8% operationally, according to the company. The release identified oncology franchises and products including DARZALEX, CARVYKTI, TECVAYLI and RYBREVANT/LAZCLUZE among growth contributors, with STELARA and other products providing offsets. The October test is whether newer growth drivers continue to outweigh those pressures after pricing, competition and mix.
Read the segment disclosure product by product. A trial update or regulatory milestone can improve a longer-term thesis without immediately creating quarterly sales. Conversely, a strong aggregate figure can mask concentration in a handful of products. Investors should ask how much growth comes from existing demand, launches, acquisitions and currency translation, rather than treating every growth percentage as interchangeable.
MedTech and the bridge to cash
Q2 MedTech reported sales were $8.926 billion, up 4.5%; operational growth was 3.6%. The company cited surgery, cardiovascular, vision and orthopaedics as contributors. For October, compare procedure volumes, product mix and margins, not simply the segment’s top line. A high-growth product may still take time to move group-level earnings materially.
The July release estimated about $8.7 billion of year-to-date free cash flow as of July 15, defining this non-GAAP measure as operating cash flow less capital expenditures. It was an estimate at that date, not a completed full-year result. Compare the next cash-flow disclosure with GAAP earnings, capital spending, working capital and any acquisition-related commitments. Our earnings-report guide explains why one adjusted EPS figure is not a complete cash-flow analysis.
Conditional October scenarios, not invented targets
Constructive case: both segments sustain operational growth, product-level disclosures support durable demand, cash conversion remains sound, and management maintains or improves the July full-year outlook. Even then, a favorable operating report does not guarantee a rising share price; valuation and prior expectations matter.
Mixed case: one segment performs well while the other weakens, or reported growth benefits from currency while operational trends soften. The right response is to revise the underlying sales and margin assumptions, not force a single headline into a buy-or-sell label.
Risk case: product competition, weaker procedure demand, litigation uncertainty, expenses or cash demands reduce confidence in future earnings. Do not invent a probability or percentage share-price decline. Inspect the company’s updated guidance, risk disclosures and the market price at the time of a decision.
A practical reading order on October 13
- Open the actual Q3 release and check its date.
- Compare Q3 reported and operational sales by segment with the July baseline.
- Read the product-level drivers and any changes in competitive or regulatory language.
- Compare GAAP and adjusted EPS and read the reconciliation.
- Check full-year sales and adjusted-EPS guidance against July’s ranges.
- Examine cash flow, capital spending and balance-sheet commentary.
- Only then weigh the new evidence against the current share price and your own risk limits.
For the dividend-policy background, see our JNJ dividend and split guide. For the prior monthly baseline, see the September 2026 JNJ outlook. This October page focuses on the imminent Q3 verification point rather than copying those analyses.
Frequently asked questions
When are JNJ’s Q3 2026 results scheduled?
Johnson & Johnson announced an October 13, 2026 release at about 6:45 a.m. Eastern Time and a call at 8:30 a.m. Eastern Time. Verify any change on its investor-relations site.
Does this guide include a JNJ price target?
No. A defensible price target needs a contemporaneous share price, valuation model and uncertain future assumptions. This is a source-based scenario framework.
Is the July 2026 guidance a Q3 result?
No. The $100.8 billion–$101.4 billion reported-sales range and $11.60–$11.75 adjusted-EPS range were full-year estimates issued with Q2 results.
Educational analysis only, not individualized investment, legal or tax advice. Sources and management estimates were checked on September 21, 2026; new disclosures can supersede them.